###### Strengths and limitations of this study

-   The Uppsala--Stockholm Assisted Reproductive Techniques (UppStART) dataset comprises a wide range of sociodemographic and lifestyle data, clinical data from medical records, biological samples (including blood, DNA, saliva, cord blood, placenta) and epigenetic data.

-   Questionnaires were completed at baseline, oocyte retrieval and during subsequent in vitro fertilisation (IVF) cycles so as to be able to assess health and lifestyle changes during and between cycles.

-   The process of linking the participants to the Swedish national health registers has been initiated and will allow for long-term follow-up of the couples and infants.

-   Possible recall bias and volunteer bias are limitations, however, UppStART participants have characteristics typical of couples undergoing IVF treatment in Sweden.

Introduction {#s1}
============

Assisted reproductive techniques (ART) include the use of hormones to downregulate pituitary function and to stimulate multiple oocyte production, in vitro manipulation of the oocyte and sperm for in vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI) procedures, and culturing of pre-implantation embryos in culture media and incubators before the embryo is transferred to the womb. Hence, ART manipulates many steps involved in natural conception and may therefore potentially alter biological processes in the fetus, which may result in short-term and long-term health consequences on the offspring. It has been well established that ART offsprings have a higher risk of being born with a low birth weight or preterm.[@R1] The reasons behind these associations are unknown, and some hypothesise that alterations in the epigenetic profile of the offspring are a contributing factor.[@R3]

Further, recent studies have indicated that a number of assisted reproduction procedures, including controlled ovarian stimulation, micromanipulation of gametes in addition to embryo culture, can cause epigenetic disruption.[@R7]

It is estimated that approximately 12%--28% of couples trying to conceive are diagnosed with infertility.[@R10] Further, nowadays, couples and especially women prioritise educational and career goals and securing economic stability, thereby delaying childbearing.[@R11] The use of ART is increasing in Sweden, as well as elsewhere in Europe, with up to 5% of all conceptions being a result of some form of ART in the Nordic countries.[@R12] However, the pregnancy success rate per ART cycle is only 28%, and the take-home baby rate is barely 25%, which is not always known to the general public.[@R13] Little is known of how lifestyle factors can affect the outcomes of ART attempts (ie, number of matured oocytes, number of embryos, pregnancy rate and miscarriage rate).

Therefore, the Uppsala--Stockholm Assisted Reproductive Techniques (UppStART) study was initiated to (1) investigate if epigenetic alterations exist in infants conceived via ART compared with those conceived spontaneously and (2) investigate if lifestyle factors (eg, caffeine consumption, cortisol levels, folate, C-reactive protein, natural products and supplements and prescribed medication use) are associated with time to pregnancy, pregnancy rates, subclinical and clinically recognised miscarriages, ART procedure-specific outcomes (eg, number and quality of oocytes and embryos, sperm characteristics), and obstetric and prenatal outcomes in ART cycles and pregnancies.

Cohort description {#s2}
==================

Study population and setting {#s2-1}
----------------------------

The UppStART study is a prospective cohort study of couples undergoing infertility treatment (specifically IVF or ICSI) in the greater Stockholm and Uppsala municipalities, which provide healthcare for approximately 3 million people. Participants were recruited from three of the four fertility and reproductive health clinics in Stockholm and one clinic in Uppsala, which also serves a large volume of patients from Stockholm. In Sweden, fertility treatments are provided within the tax-funded healthcare system. Treatments are individualised based on the identified causes of infertility.

At the time of planning their first IVF/ICSI treatment, couples were approached by the clinic's nurse or midwife and asked to participate in the study. To facilitate the process of informed consent, the couples were provided with both verbal and written information approved by the regional ethical board about the purpose of the study, methods, the voluntary nature of participation and the possible risks which included possible discomfort during blood sampling. Additionally, participants were informed that they could withdraw from the study at any time with no impact on their medical care. The requirement for inclusion in the study was an understanding of the Swedish language and exclusion was the use of donor gametes. At the time of recruitment, Swedish law did not allow single women to receive ART treatment; hence, no single women were recruited into the UppStART study. Among the couples, approximately 20% of male partners chose not to participate (n=105).

The signed consent forms were sent from the clinics to the UppStART research nurse at the host institution, the Karolinska Institute, who monitored recruitment and questionnaire responses, and reminded participants via email 2 weeks after signing the consent form to answer the baseline questionnaire if they had not done so. A second reminder by email was sent 2 weeks after the first, and if participants still had not completed the online questionnaire, the research nurse attempted to contact them by phone. No other attempts were made after the telephone call and participants were marked as non-responders. Once the ART treatment cycle began and the participants reached the stage of oocyte retrieval, they were asked to respond to a second online follow-up questionnaire ([figure 1](#F1){ref-type="fig"}).

![Timeline of participant recruitment and data collection in the Uppsala--Stockholm Assisted Reproductive Techniques study. ART, assistedreproductive techniques; ICSI, intracytoplasmic sperm injection; IVF, in vitro fertilisation.](bmjopen-2018-028866f01){#F1}

Recruitment took place from September 2011 to December 2013. IVF treatment(s) of the participants were followed until December 2014 or drop-out/consent withdrawn (n=4), whichever came first. When the couples returned to the clinic for repeated ART attempts, clinic staff collected a blood sample, provided saliva collection tubes and instructed the participants to respond to the online follow-up questionnaire.

[Figure 2](#F2){ref-type="fig"} reports the number of consented participants and the number of participants who responded to baseline and follow-up questionnaires and provided samples. The cohort includes 971 participants (n=514 women; n=457 men). Eighty percent of the cycles progressed to an embryo transfer, of which 57.6% of the embryos were created via standard IVF, and 42.4% via ICSI. From the first IVF cycle included in the study, 129 pregnancies were achieved. Only pregnancies and children conceived via IVF procedures are included in this cohort.

![Uppsala--Stockholm Assisted Reproductive Techniques study: number of participants and samples collected. IVF, in vitro fertilisation.](bmjopen-2018-028866f02){#F2}

[Table 1](#T1){ref-type="table"} shows baseline characteristics of participants and differences between responders and non-responders.

###### 

Baseline characteristics of participants in the Uppsala--Stockholm Assisted Reproductive Techniques study

  Sociodemographic characteristics   Women        Men                      
  ---------------------------------- ------------ ----------- ------------ -----------
  Age, mean*±*SD**\***               33.8±4.12    33.9±4.61   35.9±5.44    37.2±6.39
  BMI, mean*±*SD                     23.5±3.8     N/A         25.6±3.0     N/A
  Highest education**†**                                                    
   High school, n (%)                90 (21.2)    21 (26.3)   110 (32.2)   40 (37.4)
   University, n (%)                 334 (78.8)   59 (73.8)   232 (67.8)   66 (62.6)
  Current smoker, n (%)              14 (3.3)     N/A         18 (5.3)     N/A

Data for non-responders provided by Statistics Sweden.

\*Data missing for 10 non-responders.

†Data missing for 6 non-responders.

BMI, body mass index; N/A, data not available.

Data collection and measures {#s2-2}
----------------------------

### Overview {#s2-2-1}

[Table 2](#T2){ref-type="table"} and [figure 1](#F1){ref-type="fig"} provide an overview of data and sample collection in the UppStART study. After informed consent was given, the clinic staff withdrew blood samples and provided the participant with a kit for at-home saliva collection. The participants were asked to answer a web-based baseline questionnaire within a few days of their clinic visit and prior to their IVF/ICSI treatment start, which included an extensive list of questions on sociodemographic, anthropometric and lifestyle factors.

###### 

Data and sample collection in the Uppsala--Stockholm Assisted Reproductive Techniques study

  Phase                                          Measurements
  ---------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Baseline, collected prior to IVF cycle start   Questionnaire: self-reported sociodemographic, health, lifestyle and behaviour in the past 3 months or 1 year (listed in [table 2](#T2){ref-type="table"})Blood samples collected: plasma, serum, extracted DNA stored at --80°C.Saliva samples collected at 7 am and 9 pm on the same day, cortisol extracted and measured
  At oocyte aspiration                           Questionnaire, follow-up: a shorter version of the baseline questionnaire to assess if the participant changed their lifestyle factors after cycle start
  At delivery                                    Maternal blood sample (PAX gene, EDTA)Cord blood (PAX gene, EDTA)Placenta tissue and amniotic fluid, stored at −80°C
  Repeat IVF treatments                          Questionnaire, follow-up: a shorter version of the baseline questionnaire to assess if the participant changed their lifestyle factors between IVF cyclesBlood samples collected: plasma and serum stored at --80°C.Saliva samples collected at 7 am and 9 pm on the same day

EDTA, ethylenediaminetetraacetic acid; IVF, in vitro fertilisation.

### Questionnaires data {#s2-2-2}

The baseline questionnaire asked an extensive list of questions about sociodemographic, health, and lifestyle factors in the previous 3 months or the previous year (summarised in [table 3](#T3){ref-type="table"}). It has been reported that couples undergoing ART change to a healthier lifestyle or try a range of 'natural' remedies in order to improve the outcome of their fertility treatment.[@R14] Therefore, the follow-up questionnaire at oocyte retrieval and at subsequent ART procedures was a shortened version of the baseline questionnaire, designed to capture changes in lifestyle since the start of fertility treatment or since the previous cycle.

###### 

Variables included in the baseline and follow-up questionnaires in the Uppsala--Stockholm Assisted Reproductive Techniques study

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Topic                                                                                       Topic*, continued*
  ------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Sociodemography**\                                                                        **Lifestyle**\
  General:Family / householdEducation\                                                        General health\
  Occupation:Work historyShift workNight work\                                                Diet:MealsBeverages/caffeine intakeAlcohol intakeVitamins and supplements\
  Working environment:Physiological discomfort/chemical exposuresWork/private life balance\   Physical activity:Activity during occupational hoursLeisure time activitiesSport activitiesSleeping habitsMobile phone useHair colour useBath/sauna useTanning\
  **Smoking, nicotine and alcohol use**\                                                      **Self-care**\
  Smoking history\                                                                            Medication OTC\
  Current smoking†\                                                                           Complementary medicine\
  Current snus use\*†\                                                                        **Asthma and allergy**\
  Alcohol consumption\                                                                        Asthma: diagnosis, medication\
  **Reproductive health and infertility treatment**\                                          Allergies: diagnosis, medication (including hay fever, allergic rhinitis, pollen, fur, bee, wasp, contact allergy)\
  Menstruation\                                                                               **Psychosocial**\
  Contraceptive use\                                                                          General stress:Anxiety and depressionPerceived Stress Scale, 10-question version[@R27]\
  Pregnancy/giving birth\                                                                     Infertility-related psychosocial scales[@R28]:Infertility-related communication strategiesPartner communicationMarital benefit measureFertility Problem Stress ScaleAttitudes to treatmentExpectations of fertility treatment
  Gynaecological surgery\                                                                     
  Infertility/disease\                                                                        
  Sexarche\                                                                                   
  Sexually transmitted disease\                                                               
  Cause of infertility\                                                                       
  Previous infertility treatments\                                                            
  **Medical history**†\                                                                       
  Weight and gestational age at birth/prematurity\                                            
  Current height and weight\                                                                  
  Disease diagnosis:Year of diagnosisMedicationPainkiller use in the last 3 months\           
  Cancer:Year of diagnosisType of cancer and locationTreatment and medication                 

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Baseline questionnaire questions were phrased to collect information on the participants' lifestyle and behaviour in the 3 months or 1 year prior to cycle start.

\*A moist form of smokeless tobacco used in Sweden which is usually placed under the upper lip.

†These sections were included in the follow-up questionnaire issued at oocyte aspiration and at repeated IVF treatment cycles, where the questions were phrased to ask about behaviour/lifestyle since beginning IVF treatment.

IVF, in vitro fertilisation; OTC, over the counter.

### Medical records {#s2-2-3}

The medical records of each participant were collected from the four participating clinics and included data on all IVF/ICSI cycles initiated between the date of study entry and end of 2014. Clinical data included the medical and reproductive history of the participant, IVF/ICSI cycle protocol, indicators of oocyte and embryo quality and IVF cycle outcome including pregnancy. [Box 1](#B1){ref-type="boxed-text"} summarises the available clinical data.

###### Summary of available clinical data for UppStART study participants

#### Treatment data

-   Ovarian stimulation procedure clinical data

-   Type of treatment: IVF/ICSI

-   Type of culture media

-   Number of oocytes and embryos obtained

-   Indicators of oocyte quality

-   Indicators of embryo quality

-   Sperm quality variables

#### Treatment outcome data

-   Urine pregnancy test results (week 2/3 after embryo transfer)

-   Ultrasound-confirmed pregnancy (week 7 after embryo transfer)

-   Miscarriage

-   Live birth (to be supplemented by linkage to the Swedish Medical Birth Register)

ICSI, intracytoplasmic sperm injection; IVF, in vitro fertilisation; UppStART, Uppsala--Stockholm Assisted Reproductive Techniques.

### Biological samples: baseline {#s2-2-4}

#### Blood samples {#s2-2-4-1}

At the time of recruitment into the study, the clinic staff withdrew blood samples, which were then sent to the Karolinska Institutet (KI) Biobank. Plasma, serum and whole blood were aliquoted and stored at −80°C. DNA was extracted from whole blood and stored at −80°C.

#### Saliva samples {#s2-2-4-2}

Participants were provided with two pre-labelled Salivette (Sarstedt, Leicester, UK) kits, a pre-paid envelope for the return of samples to the KI Biobank and saliva collection instructions: samples were to be collected at home at 7:00 am (on awakening, before breakfast and teeth brushing) and at 9:00 pm the same day, with no eating, drinking, gum chewing, snus use or smoking within 30 min prior to collection. Saliva samples were returned to the KI Biobank by the participant via post and the samples were stored at the KI Biobank at −80°C until analysis.

Saliva cortisol levels (nmol/L) were measured by radioimmunoassay (RIA) (Orion Diagnostic, Espoo, Finland) by the Study Center of Laboratory Medicine at the Karolinska University Laboratory. The detection limit of the RIA was \<1.0 nmol/L, and the intra-assay and inter-assay coefficients of variance for this assay were 12% and 8% for the low control, and 7% and 5% for the high control, respectively.

### Biological samples: at delivery {#s2-2-5}

Staff at seven delivery units in Stockholm and Uppsala were recruited to assist in collecting samples from UppStART study participants during delivery. Delivery clinics were provided with a sample collection kit including tubes for collection of maternal blood (EDTA, PAX gene), cord blood (EDTA, PAX gene), amniotic fluid and placenta samples. Step-by-step instructions with pictures, to ensure consistent sampling technique, were provided to the midwives attending the delivery for sampling of one small piece of placenta (approx. 2×2 cm) from the centre of each quadrant, both on the maternal and fetal side, for a total of eight samples. Samples were stored in −20°C freezers at the delivery units until they were collected by UppStART study staff and deposited into the KI Biobank.

### Linkage to national registers {#s2-2-6}

Through the unique identification number assigned to each Swedish citizen at birth or immigration,[@R16] it is possible to link our study participants to the Swedish population-based national and quality registers. While no further direct participation by the UppStART study participants is currently planned, all participants consented to their study data being linked to the national population registers for long-term follow-up of themselves and of the children they conceived while being part of the study. The process to link this cohort to the registers has been initiated and will include the Medical Birth Register, Perinatal Quality Register (for neonatal intensive care), Register of Malformations, Prescription Drug Register, Inpatient and Outpatient Registers, Cause of Death Register and the Multigeneration Register.[@R17] This initial linkage will provide data from prenatal, obstetrical, neonatal and infant care, and subsequent updates will provide data on childhood health and educational outcomes.

Patient and public involvement {#s2-3}
------------------------------

Throughout the study's inception, design and execution, the Principal Investigator of the UppStART study (ANI) was herself a patient, undergoing IVF treatments. Therefore, the patient perspective was taken into account from start to end. The study was designed by ANI, in collaboration with the clinicians from the participating clinics. ANI also made regular visits to the participating clinics to discuss with clinicians about the patient reactions to the study, how they could optimise recruitment while ensuring that the delicate circumstances of the couples struggling to become pregnant were respected. Further, the questionnaires answered by the participants included a section on how they felt about answering the survey, including a free text option for them to express any concerns related to their participation in the study. These responses were monitored by ANI and the study staff as they were submitted.

Findings to date {#s3}
================

Stress {#s3-1}
------

While it is well established that women undergoing fertility treatment experience high levels of stress and higher prevalence of symptoms of depression and anxiety, it remains uncertain if and how psychological stress clinically affects the outcome of IVF treatments.[@R20] The first study completed using UppStART study data investigated the association between self-reported perceived stress, infertility-related stress and cortisol levels on IVF cycle outcomes including clinical pregnancy and indicators of oocyte and embryo quality. Overall, we found that stress measured prior to IVF cycle start was not associated with IVF cycle outcome, oocyte maturity or embryo quality. The findings from this study and many other studies reporting no association between stress and IVF outcomes are potentially reassuring to women undergoing fertility treatment and the clinicians who may have concerns about the influence of stress levels on the success of their IVF treatment.[@R23]

Cumulative impact of lifestyle factors on IVF treatment outcomes {#s3-2}
----------------------------------------------------------------

The UppStART study has been used as a validation cohort in a study examining the cumulative impact of lifestyle factors on IVF treatment outcomes. An individual as well as a cumulative effect of smoking and BMI on the number of aspirated and mature oocytes in fresh IVF treatment cycles has been found, especially among women with low ovarian reserve.[@R24]

Epigenetics {#s3-3}
-----------

In collaboration with researchers at Leiden University, the methylation profile of the cord blood of UppStART study offspring has been measured and compared with the methylation profile in the cord blood of spontaneously conceived offspring from the Swedish Born Into Life study. Details on the Born into Life study are described at length in Smew *et al*.[@R25] The UppStART study and the Born into Life study were run in parallel from the same department, with the protocols for sample collection coordinated. Genome-wide DNA methylation data were generated using the Illumina Infinium Human Methylation 450K BeadChip (450 k array). A total of 500 ng of genomic DNA isolated from cord blood was bisulfite treated using the EZ-96 DNA methylation kit (Zymo Research, Orange, California, USA). The first aim was to identify potential differences in epigenetic marks between IVF and spontaneously conceived offsprings. Further, comparisons between methylation profiles from infants conceived via different ARTs will be conducted, such as between IVF and ICSI, fresh and frozen embryos and Day 2 and blastocyst embryo transfer. The study results are currently being written up for submission for publication.

Further, while not considered in this study, the plethora of exposure information gathered from the questionnaires also provides unique possibilities to explore gene--environment interactions in the epigenetic analyses and the impact of specific environmental exposures on epigenetic marks.

Strengths and limitations {#s3-4}
-------------------------

The major strength of the UppStART study is the plethora of information from multiple sources, including an extensive questionnaire on a large number of lifestyle factors and behaviours, data from medical records, national registers, as well as biological specimens. Further, studies often only include women undergoing ART, however, the UppStART study has collected data on the male partners as well. Additionally, the study has captured repeated ART cycles within the couple and monitored the change in lifestyle factors between cycles to determine if these changes are linked to ART outcomes of interest.

However, there are also some limitations and potential sources of bias. Recruitment of participants was slower than expected, especially at the beginning of the study for a number of reasons: one of the four IVF clinics in Stockholm declined to participate and one clinic halted recruitment for 8 months due to staff restructuring. To encourage the involvement of clinic staff, study personnel visited with clinic staff every 6 months and distributed a newsletter reporting recruitment statistics for each clinic. Additionally, during the last year of recruitment, ethical approval was granted to give participating couples movie tickets on enrollment, thereby providing a small compensation for their participation. While the goal of the study was to capture every treatment of the couples, the clinics often missed collecting blood samples and reminding the participants to complete the questionnaires at subsequent cycles. Lastly, due to the urgent and demanding nature of the labour and delivery units, the collection of samples at delivery of some infants was missed. Midwives expressed that often there was not enough time to collect the number of samples requested while also fulfilling their clinical duties.

With any study including self-reported health and lifestyle information, such as this one, recall bias is an issue. The majority of the questions in the UppStART baseline questionnaire targeted specific lifestyle factors during the previous 3 months to a year. However, women and men experiencing infertility and planning to undergo infertility treatment often make changes in their lifestyle based on what they believe will maximise the chances of conception,[@R14] which will likely make the participants more aware of their lifestyle choices and consequently be able to respond to the questionnaire more accurately.

Further, volunteer bias may be another source of bias in the cohort. The UppStART study was presented to participants as a general study of lifestyle factors in IVF couples. Therefore, individuals with an interest in their lifestyle choices may choose to participate, and those with unfavourable lifestyle habits may have declined. However, the characteristics of the UppStART study are typical of the Swedish population undergoing IVF,[@R26] and a large degree of homogeneity exists in the demographic and lifestyle, including low rates of factors known to affect fertility and IVF outcome (eg, high BMI and smoking). As with the known variables, we speculate that the study sample is also likely to be relatively homogeneous with respect to unmeasured variables which will reduce the influence of confounders on studies performed with data from this cohort.

Collaboration {#s3-5}
-------------

We encourage the use of UppStART study data as a resource for epidemiological research. The data are available upon request, and more information can be found on the UppStART study webpage ([www.ki.se/meb/UppStART](http://www.ki.se/meb/UppStART))). To access the data, a proposal should be submitted to the principal investigators by an applicant with a PhD or an equivalent degree. Proposals will be evaluated and granted according to principles of ethical and scientific soundness. Applicants based outside of Sweden are required to involve collaborator(s) based at a Swedish research institution. Applications can only be granted and data provided after approval by the Stockholm Ethical Review Board. Information and instructions for applicants are available on the website (<https://ki.se/meb/uppstart>) and from Carolyn Cesta at carolyn.cesta\@ki.se.
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